Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. A live webcast and 90-day replay will be available via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – BLTE
In the Jul 15 session, BLTE gained 1.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | Investor conference notice | Neutral | +5.0% | Announcement of participation in Piper Sandler virtual ophthalmology investor symposium. |
| Jul 06 | Clinical data presentations | Positive | +5.0% | Planned oral presentations of Phase 3 DRAGON tinlarebant data at two meetings. |
| Jun 12 | NDA submission update | Positive | +4.4% | Completion of rolling NDA submission to FDA for tinlarebant in STGD1. |
| Jun 02 | Investor conference notice | Neutral | -8.2% | Participation announcement for Goldman Sachs global healthcare conference fireside chat. |
| May 20 | Earnings and pipeline update | Negative | +3.0% | Q1 2026 results with wider losses alongside progress on tinlarebant programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows BLTE often diverging from neutral or mixed corporate updates, with several conference and earnings headlines followed by price moves in the opposite direction of their fundamental tone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET.
Webcast Link Instructions
A webcast of the panel can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact:
ir@belitebio.com
